These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16293957)

  • 1. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
    Foley RJ; Metersky ML
    Respiration; 2008; 75(2):211-4. PubMed ID: 16293957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists?
    Pitsiou GG; Spyratos D; Kioumis I; Boutou AK; Nakou C; Stanopoulos I
    Ther Adv Respir Dis; 2009 Jun; 3(3):99-101. PubMed ID: 19638368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
    Sharma S; Kashour T; Philipp R
    Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.
    Baughman RP; Culver DA; Cordova FC; Padilla M; Gibson KF; Lower EE; Engel PJ
    Chest; 2014 Apr; 145(4):810-817. PubMed ID: 24177203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
    Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
    Shalev L; Langevitz P; Zandman-Goddard G
    Harefuah; 2008 Apr; 147(4):287-9, 376. PubMed ID: 18686806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological characteristics and clinical efficacy of bosentan].
    Fujimoto K; Ikenoya S
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):407-18. PubMed ID: 16462092
    [No Abstract]   [Full Text] [Related]  

  • 13. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M; Kodric M; Longo C; Vassallo FG
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
    Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan.
    Nakwan N; Choksuchat D; Saksawad R; Thammachote P; Nakwan N
    Acta Paediatr; 2009 Oct; 98(10):1683-5. PubMed ID: 19523174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bosentan for treatment of heart failure].
    Yoshimoto T; Hirata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():159-63. PubMed ID: 17571378
    [No Abstract]   [Full Text] [Related]  

  • 18. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A; Sakai E; Oyama N; Yamamoto T
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
    Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
    J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.
    Mathijssen H; Huitema MP; Bakker ALM; Mager JJ; Snijder RJ; Grutters JC; Post MC
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(1):74-78. PubMed ID: 33093771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.